הכנסות חזויות של החברה: Solid Bio (SLDB)

The target sales volume indicator reflects market growth expectations, where the value 0.00 serves as the target level. Solid Biosciences Inc. (SLDB) is attracting leading geneticists, securing staff through stock options. Financial stability is based on grants and partnerships amid negative FCF. The primary threat remains potential therapy side effects, which could wipe out the company's capitalization.

This indicator measures market expectations for future revenue, reflecting the analysts' consensus forecast regarding the business's ability to generate cash flow over the long term. For Solid Biosciences Inc. (SLDB), the trend of prospective sales is critically dependent on the reliability of external CMO contractors, as the lack of in-house capacity makes any gene therapy implementation forecasts sensitive to the operational risks of outsourcing.